核化学与放射化学2012，Vol.34Issue(1)：34-39,6.
123I的制备及其标记新型小分子融合肽的初步研究
Preparation of 123I and a New 123I Labeled Fusion Peptide
摘要
Abstract
123I with radioactivity of 11.1 TBq/(A·h) and nuclear purity of more than 98. 6% was prepared in the CS-30 cyclotron of Sichuan University via 121 Sb(α,2n)123I nuclear reaction by α-energy of 26.5 MeV and using Sb target of 62.2-64.3 mg/cm2. Furthermore, VhCDR1-VhFR2-VlCDR3, a new fusion peptide was labeled with 123I, and in vitro and in vivo of the labeled peptide was evaluated. The results show that the labeling yield of 123I-VHCDR1-VHFR2-VLCDR3 is more than 90%. The deiodination of 123I labeled VH CDR1-VHFR2-VLCDR3 in vivo is minimal, and 123I-VHCDR1-VHFR2-VLCDR3 has a high stability in vitro.关键词
123I/制备/标记/小分子融合肽VH CDR1-VH FR2-VL CDR3Key words
123I/preparation/label/fusion peptide VHCDR1-VHFR2-VLCDR3分类
医药卫生引用本文复制引用
杨远友,刘宁,范成中,廖家莉,许发伦,石福坤,兰栋,唐军..123I的制备及其标记新型小分子融合肽的初步研究[J].核化学与放射化学,2012,34(1):34-39,6.基金项目
国家自然科学基金资助项目(20671065) （20671065）
国家自然科学基础科学人才培养基金资助项目(J0830308) （J0830308）
高等学校博士点基金资助项目(20090181110001) （20090181110001）
四川省科技攻关基金资助项目(2010GZ0174) （2010GZ0174）
辐射物理及技术教育部重点实验室开放课题(2011) （2011）
